

# Expertly Navigating the Dementia Landscape



PPD's neuroscience team is committed to helping our clients strategically plan and efficiently operationalize studies to deliver therapies confidently, quickly and within budget. Our team has wide-ranging experience and can support each client with the in-depth knowledge to navigate and execute complex dementia trials.



**15 dementia studies**

Alzheimer's disease and Lewy body dementia



**420+ sites**


involving



**1,000+ patients**

in the past five years

We specialize in navigating the shifting research landscape, mitigating recruitment risks and applying our vast knowledge of multinational standards and local requirements. In addition, we provide scientific and regulatory consultation, and apply our operational experience across a variety of study designs.



**In-depth Alzheimer's Experience** PPD has the experience and expertise to successfully conduct Alzheimer's disease studies and navigate complex regulatory processes.

## Our Alzheimer's studies involved:



Symptomatic treatment and disease modification approaches



Pre-symptomatic patient identification and intervention



Phase I and dose ranging



Biological markers and imaging

- Cerebrospinal fluid (CSF) A-beta and CSF tau/p-tau
- Volumetric brain assessment
- Amyloid PET imaging/In vitro amyloid plaque density measurement

Our neuroscience team is therapeutically aligned, allowing our trials to be driven by experts with comprehensive experience in the indications being studied. Additionally, our therapeutically aligned project teams are well versed in considerations often unique to Alzheimer's research, which helps ensure the safety of a vulnerable subject population.

# Expertly Navigating the Dementia Landscape

## Optimized Recruiting and Retention of Well-defined Patients

To mitigate the recruitment and retention challenges often seen in Alzheimer's trials, we maintain

an extensive global network of qualified and experienced investigators made up of neurologists, gerontologists, psychiatrists and internal medicine/general practitioners.

We also leverage Synexus, the wide-reaching site network, as well as other top site networks and Acurian, an industry-leading patient recruitment organization.

As an additional level of assurance to confirm that the appropriate patients are entered into trials, we offer a prospective-protocol, specific-targeted eligibility review service through our team of neuroscience physicians.

## Quality and Endpoint Fidelity

Because many of the key endpoints in dementia studies are subjective in nature, an understanding of the impact of cultural and language differences on cognitive and functional assessments is critical. Additionally, experience and expertise in selection and management of rater services are paramount so that rater reliability is optimized, variability is minimized and overall study quality is assured. We understand the importance of these factors and are well-positioned to navigate them through our network of strategic suppliers who specialize in support services typically associated with the conduct of clinical trials in Alzheimer's disease, including rater training and endpoint validation, instrument procurement/licensing, and translation and imaging.

To retain patients in our studies, we offer patient-centric solutions to help ease the burden on trial participants and their caregivers.



home health care services



travel services



drug delivery options